Cargando…

Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics

Parkinson’s disease (PD) is a prevalent neurodegenerative illness that is often diagnosed after significant pathology and neuronal cell loss has occurred. Biomarkers of PD are greatly needed for early diagnosis, as well as for the prediction of disease progression and treatment outcome. In this rega...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakubowski, Jennifer L., Labrie, Viviane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302044/
https://www.ncbi.nlm.nih.gov/pubmed/27792016
http://dx.doi.org/10.3233/JPD-160914
_version_ 1782506470022053888
author Jakubowski, Jennifer L.
Labrie, Viviane
author_facet Jakubowski, Jennifer L.
Labrie, Viviane
author_sort Jakubowski, Jennifer L.
collection PubMed
description Parkinson’s disease (PD) is a prevalent neurodegenerative illness that is often diagnosed after significant pathology and neuronal cell loss has occurred. Biomarkers of PD are greatly needed for early diagnosis, as well as for the prediction of disease progression and treatment outcome. In this regard, the epigenome, which is partially dynamic, holds considerable promise for the development of molecular biomarkers for PD. Epigenetic marks are modified by both DNA sequence and environmental factors associated with PD, and such marks could serve as a unifying predictor of at-risk individuals. Epigenetic abnormalities have been detected in PD and other age-dependent neurodegenerative diseases, some of which were reported to occur early on and were reversible by PD medications. Emerging reports indicate that certain epigenetic differences observed in the PD brain are detectable in more easily accessible tissues. In this review, we examine epigenetic-based strategies for the development of PD biomarkers. Despite the complexities and challenges faced, the epigenome offers a new source of biomarkers with potential etiological relevance to PD, and may expand opportunities for personalized therapies.
format Online
Article
Text
id pubmed-5302044
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-53020442017-02-28 Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics Jakubowski, Jennifer L. Labrie, Viviane J Parkinsons Dis Review Parkinson’s disease (PD) is a prevalent neurodegenerative illness that is often diagnosed after significant pathology and neuronal cell loss has occurred. Biomarkers of PD are greatly needed for early diagnosis, as well as for the prediction of disease progression and treatment outcome. In this regard, the epigenome, which is partially dynamic, holds considerable promise for the development of molecular biomarkers for PD. Epigenetic marks are modified by both DNA sequence and environmental factors associated with PD, and such marks could serve as a unifying predictor of at-risk individuals. Epigenetic abnormalities have been detected in PD and other age-dependent neurodegenerative diseases, some of which were reported to occur early on and were reversible by PD medications. Emerging reports indicate that certain epigenetic differences observed in the PD brain are detectable in more easily accessible tissues. In this review, we examine epigenetic-based strategies for the development of PD biomarkers. Despite the complexities and challenges faced, the epigenome offers a new source of biomarkers with potential etiological relevance to PD, and may expand opportunities for personalized therapies. IOS Press 2017-02-07 /pmc/articles/PMC5302044/ /pubmed/27792016 http://dx.doi.org/10.3233/JPD-160914 Text en IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Jakubowski, Jennifer L.
Labrie, Viviane
Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics
title Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics
title_full Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics
title_fullStr Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics
title_full_unstemmed Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics
title_short Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics
title_sort epigenetic biomarkers for parkinson’s disease: from diagnostics to therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302044/
https://www.ncbi.nlm.nih.gov/pubmed/27792016
http://dx.doi.org/10.3233/JPD-160914
work_keys_str_mv AT jakubowskijenniferl epigeneticbiomarkersforparkinsonsdiseasefromdiagnosticstotherapeutics
AT labrieviviane epigeneticbiomarkersforparkinsonsdiseasefromdiagnosticstotherapeutics